On October 25, 2024 Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, reported that it will present a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, TX (Press release, Traverse Biotech, OCT 25, 2024, View Source [SID1234647431]). The presentation will showcase preclinical results on TB-Bs1, Traverse’s T-cell engaging product candidate targeting ROR2-positive solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: ROR2-targeted T-cell engager as a novel therapeutic approach in solid tumors
Abstract Number: 1065
Location: Exhibit Halls A-B, George R. Brown Convention Center
Date: Friday, November 8, 2024
Attending from Traverse Biotech:
Brandy Houser, Ph.D., Co-Founder & Chief Executive Officer
Jing Gong, Ph.D., Director of Strategy and Operations
About TB-Bs1
TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody platform targeting ROR2. ROR2 is a receptor that has been shown to cause cancer cell proliferation and that has also been identified as a negative prognostic indicator. ROR2 is a member of the receptor tyrosine kinase-like orphan receptor family associated with Wnt signaling. We and others have confirmed ROR2 protein expression in liquid and solid cancers, with TB-Bs1 demonstrating consistent cytotoxic activity against ROR2-positive cancer cell lines. In a humanized mouse model, TB-Bs1 significantly inhibited tumor growth in a dose-dependent manner with minimal adverse effects. These results highlight the potential of TB-Bs1 as a targeted immunotherapy for ROR2-positive cancers.